Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus-A Systematic Review and Meta-analysis

被引：0
|
作者：
Satti, Muniza M.
O'Brien, Timothy
Liew, Aaron
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1108-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical Characteristics and Treatment Patterns among Glucagon-Like Peptide Receptor Agonist (GLP-1RA) Users in a US EHR and Claims Linked Database
    Girguis, Mariam S.
    Lillie, Mark
    Bodner, Eric
    Kasrai, Cordie K.
    Spencer, Jessica R.
    Nunez, Ana Paula Cancino
    O'Kelly, James
    DIABETES, 2024, 73
  • [42] A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus
    Thondam, S. K.
    Cuthbertson, D. J.
    Aditya, B. S.
    MacFarlane, I. A.
    Wilding, J. P.
    Daousi, C.
    CLINICAL ENDOCRINOLOGY, 2012, 77 (04) : 635 - 637
  • [43] Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Use on Retained Gastric Contents and Adverse Events With Upper Endoscopy: A Systematic Review and Meta-Analysis
    Rahman, Syed Hamaad
    Khan, Nihal I.
    Farooq, Aimen
    Shafique, Nouman
    Qureshi, Mahir
    Mohamed, Islam
    Musallam, Rami
    Hurairah, Abu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S):
  • [44] GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA): IMPACT ON OUTPATIENT UPPER ENDOSCOPY PROCEDURE QUALITY
    Peng, Frederick B.
    Rivera, Andres C. Urias
    Devalaraju, Samanthika S.
    Liu, Keith
    Hashimoto, Robert T.
    Baerman, Elliot
    Larson, Scott
    GASTROENTEROLOGY, 2024, 166 (05) : S646 - S646
  • [45] Use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in dialysis patients
    Pelz, Stefan
    Schwarz, Albin
    Ambuhl, Patrice
    SWISS MEDICAL WEEKLY, 2020, : 38S - 38S
  • [46] In Insulin-Naive Patients with T2DM Uncontrolled on GLP-1 Receptor Agonists (GLP-1RA), IDegLira (Novel Combination of Insulin Degludec plus Liraglutide) Resulted in Improved Patient-Reported Outcomes vs. Unchanged GLP-1RA
    Linjawi, Sultan
    Brod, Meryl
    Bode, Bruce W.
    Chaykin, Louis B.
    Courreges, Jeanpierre
    Handelsman, Yehuda
    Kongso, Jens Harald
    Reiter, PanagIota Diamantopoulou
    Simpson, Richard W.
    DIABETES, 2015, 64 : A296 - A296
  • [47] Efficacy and Safety of IDegLira (Combination of Insulin Degludec plus Liraglutide), in Insulin-Naive Patients with T2D Uncontrolled on GLP-1 Receptor Agonist (GLP-1RA) Therapy
    Linjawi, Sultan
    Bode, Bruce W.
    Chaykin, Louis B.
    Courreges, Jean-Pierre
    Handelsman, Yehuda
    Lehmann, Lucine
    Mishra, Abhishek
    Simpson, Richard W.
    DIABETES, 2015, 64 : A255 - A255
  • [48] IMPACT OF GLP-1RA ON HEART RATE, BLOOD PRESSURE AND HYPERTENSION AMONG TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Sun, F.
    Wu, S.
    Chai, S.
    Yang, Z.
    Yu, K.
    Zhan, S.
    VALUE IN HEALTH, 2014, 17 (07) : A719 - A720
  • [49] Effect of Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) on Hypertension-Induced Atrial Remodelling
    Zhang, Zhe Yu
    FASEB JOURNAL, 2018, 32 (01):
  • [50] Safety and Efficacy of Long-Term Use of GLP-1RA in Post-Transplant Diabetes Mellitus (PTDM): Analysis of Dulaglutide vs. Liraglutide
    Mallik, Ritwika
    Mukuba, Dorcas
    Casabar-Licayan, Mahalia
    Fan, Stanley
    Mccafferty, Kieran
    Ali, Omer
    Yaqoob, Muhammad Magdi
    Chowdhury, Tahseen A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 558 - 558
12345